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Abstract
Background: Cervical cancer is associated with a high yearly mortality. The presence of persistent disease after
radiotherapy is a significant predictor of patient survival.
The aim of our study was to assess if tumor volume regression measured with MR imaging at the time of
brachytherapy can discriminate between patients who eventually will achieve a complete response to radiotherapy
from those who will not. The second objective was to evaluate whether tumor volume regression predicts overall
treatment failure.
Methods: MRI was evaluated quantitatively in 35 patients; by means of tumor volumetry on T2-weighted MR
images before treatment, at the first BCT application, and at the final BCT. The MR images were independently
analyzed by two investigators. As a reference standard histopathologic confirmation of residual tumor and/or
clinical exam during follow-up > 1 year were used. Area under the curve were compared, P-values <0.05 were
considered significant.
Results: There was a good correlation between volume measurements made by the two observers. A residual tumor
volume >9.4 cm3 at final BCT and tumor volume regression < 77 % of the pre-treatment volume were significantly
associated with local residual tumor after completion of therapy (p < 0.02) (AUC, 0.98-1.00). A volume >2.8 cm3 at final
BCT was associated with overall treatment failure (p < 0.03).
Conclusion: Our study shows that volume analysis during BCT is a predictive tool for local tumor response and overall
treatment outcome. The potential of local response assessment to identify patients at high risk of overall treatment
failure is promising.
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Background
Cervical cancer is associated with a yearly mortality
of 270.000 patients [1–3]. The presence of a persist-
ent cervical carcinoma after radiotherapy is a signifi-
cant predictor of patient survival. In a select group of
patients with persistent tumors after radiotherapy,
surgical resection can be beneficial [4, 5].
The detection of residual tumors by gynecological
examination, MRI, and PET-CT is complicated by the
occurrence of false positive results and interobserver
dependency, which are mainly due to post-radiation
induced fibrosis. Diagnoses based on histological bi-
opsies are limited by the occurrence of false negative
results [6–9]. It has been reported that tumor volume
assessment on repeated MRIs during radiotherapy
treatment can be used to predict tumor response to
radiotherapy [10–13]. In the past decade a new con-
cept was clinically introduced by the GEC-ESTRO
working group taking the tumor regression during ex-
ternal beam radiation into account for treatment
planning with brachytherapy (BCT) [14]. Applying
this concept, i.e., MR-image guided adaptive brachy-
therapy (IGABT), assessing the residual tumor volume
and/or target volume at high risk at the time of BCT
has been demonstrated to improve outcome signifi-
cantly in locally advanced cervix carcinoma [14–16].
For optimal assessment of residual tumor burden at
the time of BCT T2-weighted MR images are ob-
tained with the BCT applicator in place. This imaging
sequence results in the best quality to discriminate
tumor from cervical stroma. Applicator based distor-
tions and artefacts are acceptable for T2W sequences
using MR-compatible applicators [17].
Until now, volumetric analysis for predicting treatment
response on MRI used in this setting, with the BCT ap-
plicator in place, has never been used. If MR-based
tumor volume assessment at the time of BCT is a reli-
able option, it could be used to predict tumor response
both local and for overall outcome.
The aim of our study was to assess if absolute tumor
volume and tumor regression at the time of BCT can
discriminate between patients who eventually achieve a
complete response from those who do not. The second
objective was to evaluate whether local volume regres-
sion can predict overall treatment failure.
Methods and materials
Patients
We performed a retrospective analysis of patients with
primary cervical cancer (International Federation of
Gynecology and Obstetrics (FIGO) stages ≥ IB), who
were referred to our center (Maastricht University Med-
ical Centre en MAASTRO clinic) between March 2008
and August 2010 for radiotherapy. Inclusion criteria
consisted of: (1) a histologically proven primary cervical
carcinoma; (2) availability of MRI images before treat-
ment (a), after EBRT at the first BCT application (b) and
at the last BCT treatment (c); (3) treatment consisting of
EBRT (46.0–50.4 Gy and high-dose-rate BCT, with or
without concomitant chemotherapy (CT) or hyperther-
mia (HT); and (4) absence of distant metastasis at
diagnosis.
Radiotherapy protocol
For external beam radiation (EBRT) a dose of 45-
50.4 Gy was delivered in 25-28 daily fractions, 5 days a
week. Dose specification and homogeneity requirements
were according to ICRU-50. In case of concomitant
chemotherapy or regional hyperthermia, these modal-
ities were applied once-weekly during EBRT. The first
BCT was scheduled in the final week of EBRT of follow-
ing EBRT. For brachytherapy MR-compatible applicators
(Nucletron) were used placing an intra-uterine tandem
and vaginal ovoids with or without the use of interstitial
needles. For BCT planning the GEC-ESTRO guidelines
were followed, contouring the gross tumor, a high-risk
(HR) and intermediate risk clinical target volume (IR-
CTV) and the organs at risk. Typically 3 applicator in-
sertions were performed under general anesthesia with
one week interval. For the second BCT procedure the
applicator was left in place for one night allowing 2 BCT
treatments with an interval of at least 15 h. Hence, 4
BCT treatments were delivered in 2 weeks. A dose of
7 Gy per fraction was aimed to prescribe to the HR-
CTV, aiming to deliver a D90 ≥ 85 Gy.
MRI protocol
MRI was performed with a 1.5-Tesla MRI unit (Intera
(Achieva); Philips Healthcare, Best, The Netherlands or
Siemens Magnetom Avanto, Erlangen, Germany) in
52 % of the studies and with a 3.0-Tesla MRI unit
(Achieva 3.0TX; Philips Healthcare, Best, the
Netherlands) in 48 % of the studies. Patients were placed
in a feet-first supine position. The protocol consisted of
2D T2-weighted (T2W) fast spin-echo images (TR/TE
3200–5830/122–150 msec, 18–24 ETL, 3–4 NSA,
0.98 × 0.98 × (3.5–5.0) mm3 voxel at 1.5 T and TR/TE
7000/150, 28 ETL, 2 NSA, 0.98 × 0.98 × (3.00–4.00) mm3
voxel at 3 T). Scans were made in three planes (sagittal,
axial, and coronal), while the axial and coronal planes
were angled perpendicular and parallel to the cervical
axis, respectively. Patients did not receive bowel prepar-
ation or anti-spasmodic agents. MRI was performed at
different time points: before treatment (a), after EBRT at
the first BCT application (b), and at the final BCT treat-
ment (c). All MRI scans (except the first one, before the
onset of radiotherapy) were performed immediately
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before the BCT fractions were given but with the BCT
applicator in situ.
Image evaluation
MRI was evaluated quantitatively; by means of tumor
volumetry on T2-weighted MR images before treatment
(a), after EBRT at the first BCT application (b), and at
the final BCT treatment (c).
The MR images were independently analyzed by the
investigator (JEM) and a radiation oncologist (FC)
blinded to patient information and patient outcome.
Volumetric measurements of the tumors on the MR im-
ages at all three time points were performed by the two
readers, independently, and the readers were blinded to
each other’s results. All measurements were performed
on a DICOM based system for diagnostic images, Intelli-
Space PACS, (Philips Healthcare, Best, The Netherlands).
Using these measurements, a suspected tumor was de-
fined as an isointense mass within the irradiated tumor
bed in concordance with the GEC-ESTRO guidelines for
depicting gross tumor volume. Tumor volume was cal-
culated by placing freehand regions of interest along the
border of the suspected tumor on T2W sagittal or trans-
versal MR images, to obtain the sectional tumor area of
each tumor-containing slice, and multiplying the sec-
tional tumor area obtained with section thickness [18]
(Fig. 1).
The tumor volume reduction (Δvolume) was calcu-
lated as the absolute volume obtained from the post-
treatment MRI scan minus the initial tumor volume
obtained from the pre-treatment MRI scan divided by
the initial tumor volume obtained from the pre-
treatment MRI scan: [18] ((post-volume – pre-volume)/
pre-volume) *100.
Standard of reference
The presence or absence of a local residual tumor (in
cervix and/or vagina, parametria, bladder, or rectum)
was determined by:
(1) histopathology of the surgical resection specimen
(n = 11);
(2) the results of a post-treatment gynecologic
examination (under anesthesia, with or without
biopsy) performed 3 months after completion of the
entire radiation treatment and after at least
12 months of documented follow-up (n = 24).
The presence of distant metastases was proven either
by histopathology or the detection of a growing tumor
mass during subsequent imaging analysis. Overall treat-
ment failure was defined as the presence of local residual
or recurrent tumor (histologically proven), distant me-
tastases, or both.
Statistical analysis
Statistical analyses were performed using SPSS Statistics
v18.0 (SPSS Inc, Chicago, Ill.) and Stata v11.0 (StataCorp
LP, Texas). Interobserver variations were assessed by
means of interclass correlation coefficients for single and
average measures.
Receiver operating characteristics (ROC) curves were
constructed to evaluate diagnostic performance for (a)
absolute MRI volume measurements and (b) volume re-
gression (Δvolume). Corresponding areas under the
ROC curve (AUC), sensitivity, specificity, and positive
and negative predictive values were calculated according
to the optimal cut off, determined according to the point
nearest to the upper left corner in the ROC curve. Sensi-
tivities and specificities for the different scoring methods
Fig. 1 Volume measurement of cervical carcinoma, pre-treatment, at first and final BCT
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were compared using the McNemar test for paired data
or the chi-squared test for unpaired data. AUCs were
compared according to the method described by De
Long et al. [19].
P-values less than 0.05 were considered statistically
significant.
Results
A total of 48 consecutive patients were identified, of
which 35 met the inclusion criteria. Their baseline char-
acteristics are presented in Table 1.
Patient and treatment characteristics
After treatment, a local residual tumor was histologically
proven by biopsy in four patients, of whom one patient
had concurrent distant metastases and one patient had
concurrent lymphatic metastases. Six patients had dis-
tant metastases only. Two had distant or lymphatic me-
tastases. Six patients had distant metastases only. At a
median follow-up of 22 months (range, 13–41), the
remaining 25 patients were still free of disease.
MRI volumetry for detection of local residual tumor
The absolute volume measurements of both observers
are shown in Table 2. A significant decrease in tumor
volume during treatment was observed in all patients
(p ≤ 0.01). The AUC, interclass correlation coefficients,
sensitivity and specificity for absolute volume, and
volume regression are shown in Table 3. There was a
good correlation between the absolute volume measure-
ments made by the two observers (interclass correlation
coefficients, 0.90–0.98).
A tumor volume at first BCT >11.5 cm3 predicted
local residual tumor following treatment (p < 0.03). A
volume >9.4 cm3 at the final BCT and <77 % volume re-
gression compared to the pre-treatment volumes ob-
tained with MRI (Δvolume) were associated with a local
residual tumor after completion of therapy (p < 0.02)
(AUC, 0.98–1.00).
MRI volumetry for prediction of overall treatment failure
The interclass correlation coefficients, AUC, and the p-
values for absolute volume and volume regression are
shown in Table 4. A tumor volume >2.8 cm3 at the final
BCT was statistically associated with overall treatment
failure (p < 0.03) (AUC, 0.79–0.81). Also, <89 % tumor
volume regression (Δvolume) compared to the pre-
treatment volume assessed with MRI scan significantly
predicted overall treatment failure (AUC 0.87–0.78).
Discussion
Our study shows that absolute volume measurements as
well as volume regression determination at the time of
the final BCT are accurate predictors for treatment out-
come. Performing volume measurements, i.e., the abso-
lute tumor volume and tumor volume regression
(Δvolume) at the time of the final BCT treatment pre-
dicted residual tumor after treatment and overall treat-
ment failure during follow-up. Volume analysis at first
BCT gave promising results however volumetry during
the final BCT was superior for predicting residual dis-
ease. Indicative for the impact of BCT treatment for
treatment outcome in these tumors. As the results of ab-
solute volume analysis were comparable to those of vol-
ume regression analysis, absolute volume measurements
for the prediction of residual tumor after BCT could be
a better option in general practice because it is less
time-consuming.
The presence of persistent disease after radiation treat-
ment is a significant predictor of patient survival, early
detection of tumors in this group of patients is of clinical
importance. For patients with residual disease situated in
cervical or adjacent tissue, surgical resection after radi-
ation treatment can be beneficial [4, 5]. To date, most
patients receive expectant management until disease re-
currence, which might lead to more extensive surgery
with increased morbidity or to a situation where the pa-
tient might not even be operable because of large tumor
size, local involvement of bladder or bowel, distant me-
tastasis, or extensive radiation induced fibrosis. As
radiation-induced fibrosis in the target area is lower after
Table 1 Baseline Characteristics
Age median(range) 53 years (32–77)
Histology
Squamous cell carcinoma 28 (80 %)
Adenocarcinoma 5 (14 %)
Other 2 (6 %)
FIGO
I
Ib1 5 (14 %)
Ib2 4 (11 %)
II
IIa 5 (14 %)
IIb 17 (49 %)
III
IIIa 0
IIIb 2 (6 %)
IV
IVa 2 (6 %)
Therapy
Chemo-radiotherapy 29 (83 %)
Hyperthermia-radiotherapy 6 (17 %)
FIGO: The International Federation of Gynecology and Obstetrics
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completion of EBRT, surgery is an easier option at that
time.
Outcome in locally advanced cervix carcinoma has sig-
nificantly improved through dose escalation enabled by
IGABT [14]. The introduction of IGABT resulted in an
increase in overall local control (91–95 %) and a reduc-
tion of late toxicity by 50–60 % [14]. Our results show
that volumetric analysis during radiation treatment can
predict treatment failure for individual patients. In these
patients therapy could be further tailored to for example
surgery and/or adjuvant systemic treatment.
Several groups have performed semi-objective volu-
metric tumor measurements for the assessment of treat-
ment responses [10–13, 20, 21]. Most of these studies
were performed retrospectively with small study popula-
tions, the imaging protocols employed differed from
study to study, and volume evaluations were obtained
using ellipsoid based volume measurements, which are
inferior to those obtained by manual and freehand delin-
eation of regions of interest [18].
Mayr et al. reported the results of MRI-based volume
analysis during treatment at a single institution [10–13].
Table 2 Absolute MRI tumor volume measurements and regression before treatment, at first and at final brachytherapy during
radiotherapy treatment of cervical cancer
Evaluation Observer 1 Observer 2
volume (cm3) Δvolume(%) volume (cm3) Δvolume(%)
Local complete response (n:31)
(a) MRI before treatment 33 (13–104) - 33 (11–130) -
(b) MRI at the first BCT* 8.5 (0.4–28) 73 % (48–97) 8 (1–23) 73 % (37–95)
(c) MRI at the final BCT* 3.7 (0–14) 88 % (75–100) 3.3 (0.5–9) 89 % (80–100)
Local residual tumor (n:4)
(a) MRI before treatment 32 (15–44) - 28 (19–37) -
(b) MRI at the first BCT 18 (14–23) 36 % (8–55) 16 (10–23) 39 % (21–68)
(c) MRI at the final BCT 13 (4–15) 53 % (21–67) 11 (3–13) 55 % (28–74)
*p ≤ 0.01 compared to the residual tumor group
Table 3 Diagnostic performance of volume measurements for depicting local residual cervical tumor using MRI before treatment, at
first and final BCT
Evaluation AUC Interclass coefficient
(average)
Cut-off Sensitivity and specificity
Observer 1 Observer 2 Observer 1 Observer 2
Sensitivity Specificity Sensitivity Specificity












0.98 (0.94–1.00) 1.00 (1.00–1.00) 0.94 (0.89–0.97) 9,4 cm3 100 % (40–100) 94 % (77–100) 100 % (40–100) 100 % (86–100)












1.00 (1.00–1.00) 1.00 (1.00–1.00) 0.97 (0.95–0.99) 77 % 100 % (40–100) 97 % (81–100) 100 % (40–100) 100 % (86–100)
AUC are given with the corresponding 95 % confidence intervals. *p < 0.05, compared to (a)
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Wang and Mayr et al. prospectively assessed reductions
in tumor volumes measured by sequential MRI during
treatment and found a correlation between the volume
reduction ratio and 5-year local control rates [13]. Vol-
ume regression after EBRT (40–50 Gy) and not initial
tumor volume was the most accurate predictor for local
control and disease free survival. They found that a
tumor with an initial volume >40 cm3 and a residual vol-
ume >20 % after EBRT on an MRI scan is a predictor of
local treatment failure (Sensitivity 89 % and Specificity
89 %) [13].
In contrast to our study, Mayr et al. reported perform-
ing volumetric analysis without BCT applicators in place,
necessitating an additional MRI scan. This consequently
increases costs and requires the patient to come in the
MR unit at a separate time.
The quality of the MRI performed during brachyther-
apy with the applicator in situ has shown to be sufficient
for brachytherapy treatment planning. System based dis-
tortion due to the use of a magnetic field are generally
under 1-2 mm and are at their lowest in the center of
the image. Additional geometric distortions caused by
adding a MR-compatible applicator have shown to be
nearly undetectable and are at their lowest in the center
of the image [22–24]. In general MRI and applicator in-
duced reconstruction uncertainties are smaller than the
uncertainties induced by tumor contouring and bowell
movement.
As the use of MRI-guided BCT for a cervical carcin-
oma larger than 5 cm is expected to increase signifi-
cantly in future as more institutions perform 3D
treatment planning instead of 2D X-ray, volumetric ana-
lyses based on routine MRI could prove to be more cost
effective and convenient [14, 16, 25, 26].
The prevalence of recurrent/persistent local tumors in
our dataset (11.4 %) is rather low compared to those
previously reported. The low recurrence rate could be
due to the lower initial tumor volumes, which in 80 % of
our population were <40 cm3, or to several other
reasons. First, because of the exclusion criteria, patients
who did not finish imaging or the treatment protocol be-
cause of early progressive disease were excluded. Second,
all patients received together with radiation therapy,
concurrent chemotherapy or hyperthermia treatment,
which resulted in a higher cure rate than that of radio-
therapy alone [27, 28]. Third, all patients received MRI-
based high-dose-rate intracavitary and interstitial BCT
according to the GEC-ESTROO guidelines, which is
proven to be superior to 2D-based radiotherapy, espe-
cially for cervical carcinomas sized >5 cm [26]. More-
over, we included tumors that were relatively smaller
than those reported in other studies.
Our study had some limitations. First, the absence of
residual disease was not proven histopathologically in all
patients. This was mainly because some patients did not
undergo surgery. However, we believe that long-term
follow-up in the absence of recurrence is at least as good
as performing surgico-pathologic analysis. Especially be-
cause in those cases the time interval between patho-
logic analysis with random biopsies or adjuvant surgery
is shorter and it could be that because of this reason
microscopic tumors are still existent. Possible this would
not have been the case with longer waiting time, because
of delayed radiotherapy effects. A second limitation of
this study was the small number of patients. MRI-
based BCT became the standard protocol in our cen-
ter in October 2008, which was the main reason for
the exclusion of 13 patients who underwent only one
MRI scan during BCT.
Conclusion
Volume measurement at the time of BCT is a potential
promising predictor of local tumor response in individ-
ual patients, especially when performed during the final
BCT. As absolute volumetric analysis yielded results
comparable to those of volume regression analysis, a sin-
gle tumor volume measurement at the time of the last
BCT, could already be sufficient to reduce measurement
Table 4 Diagnostic performance of volume measurements for assessing overall treatment failure using MRI before treatment, at first
BCT and final BCT




Observer 1 Observer 2
Absolute volume analysis (n:35)
(a) MRI before treatment 0.56 (0.37–0.75); - 0.57 (0.38–0.76); - 0.98 (0.96–0.99) 28,6 cm3
(b) MRI at the first BCT 0.82 (0.69–0.96); p < 0.01 0.78 (0.63–0.93); p = 0.02 0.95 (0.91–0.98) 7,7 cm3
(c) MRI at the final BCT 0.81 (0.67–0.96); p < 0.01 0.79 (0.63–0.95); p = 0.03 0.94 (0.89–0.97) 2,8 cm3
Volume regression analysis (n:35)
First BCT MRI/MRI before treatment 0.87 (0.75–0.99); p < 0.01 0.78 (0.72–1.00); p = 0.11 0.94 (0.87–0.97) 72 %
Final BCT MRI/MRI before treatment 0.84 (0.69–0.89); p = 0.02 0.79 (0.63–0.95); p = 0.10 0.97 (0.95–0.99) 89 %
AUC are given with the corresponding 95 % confidence intervals
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time. We also observed an association between overall
treatment failure and local volume response, the poten-
tial of assessing local response for identifying individual
patients at high risk for overall treatment failure is
promising. External validation however in a larger and
independent study population is warranted.
Competing interest
This multidisciplinary research (radiology, gynecology and radiation
oncology) was performed by GROW (School for Oncology and
Developmental Biology, Maastricht, The Netherlands). All authors entitled to
authorship are listed as author, there are no other acknowledgments. There
are no conflicts of interests to be reported.
Authors’ contribution
JM (MD) scored the volumes on the MRI, gathered and interpreted all
patient information and research results in collaboration with DL (MD) and
BS, (Gynecological Oncologist). DL, BS and JM were the writers of the
manuscript. FB is one of the Radiologists who added with the scoring of the
MRI scans. FC is the Radiation Oncologist (second observer) responsible for
scoring all MRI volumes. LL is the Radiation Oncologist responsible for
patient data for radiation treatment and follow-up. AK, TvanG and RK were
the Gynecological Oncologists supervising research results and the writing of
the manuscript. RB-T was the Radiologist supervising research results and the
writing of the manuscript. All authors read and approved the final
manuscript.
Author details
1Department of Obstetrics & Gynaecology, Maastricht University Medical
Centre, Postbus 58006202AZ, Maastricht, The Netherlands. 2GROW, School for
Oncology and Developmental Biology, Maastricht, The Netherlands.
3Department of Radiology, Maastricht University Medical Centre, Maastricht,
The Netherlands. 4MAASTRO clinic, Postbus 30356202NA, Maastricht, The
Netherlands. 5Department of Radiology, The Netherlands Cancer Institute,
Amsterdam, The Netherlands.
Received: 24 September 2015 Accepted: 26 November 2015
References
1. Babar S, Rockall A, Goode A, Shepherd J, Reznek R. Magnetic resonance
imaging appearances of recurrent cervical carcinoma. Int J Gynecol Cancer.
2007;17(3):637–45. doi:10.1111/j.1525-1438.2007.00849.x.
2. Elit L, Fyles AW, Devries MC, Oliver TK, Fung-Kee-Fung M. Follow-up for
women after treatment for cervical cancer: a systematic review. Gynecol
Oncol. 2009;114(3):528–35. doi:10.1016/j.ygyno.2009.06.001.
3. Kitchener HC, Hoskins W, Small Jr W, Thomas GM, Trimble EL. The
development of priority cervical cancer trials: a Gynecologic Cancer
InterGroup report. Int J Gynecol Cancer. 2010;20(6):1092–100. doi:10.1111/
IGC.0b013e3181e730aa.
4. Hong JH, Tsai CS, Lai CH, Chang TC, Wang CC, Chou HH, et al. Recurrent
squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat
Oncol Biol Phys. 2004;60(1):249–57. doi:10.1016/j.ijrobp.2004.02.044.
5. Houvenaeghel G, Lelievre L, Buttarelli M, Jacquemier J, Carcopino X, Viens P,
et al. Contribution of surgery in patients with bulky residual disease after
chemoradiation for advanced cervical carcinoma. Eur J Surg Oncol. 2007;
33(4):498–503. doi:10.1016/j.ejso.2006.10.011.
6. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E,
et al. Gynecologic examination and cervical biopsies after (chemo) radiation
for cervical cancer to identify patients eligible for salvage surgery. Int J
Radiat Oncol Biol Phys. 2006;66(3):699–705. doi:10.1016/j.ijrobp.2006.05.039.
7. Vincens E, Balleyguier C, Rey A, Uzan C, Zareski E, Gouy S, et al. Accuracy of
magnetic resonance imaging in predicting residual disease in patients
treated for stage IB2/II cervical carcinoma with chemoradiation therapy:
correlation of radiologic findings with surgicopathologic results. Cancer.
2008;113(8):2158–65. doi:10.1002/cncr.23817.
8. Hatano K, Sekiya Y, Araki H, Sakai M, Togawa T, Narita Y, et al. Evaluation of
the therapeutic effect of radiotherapy on cervical cancer using magnetic
resonance imaging. Int J Radiat Oncol Biol Phys. 1999;45(3):639–44.
9. Manfredi R, Maresca G, Smaniotto D, Greggi S, Andrulli D, Rabitti C, et al.
Cervical cancer response to neoadjuvant therapy: MR imaging assessment.
Radiology. 1998;209(3):819–24.
10. Mayr NA, Magnotta VA, Ehrhardt JC, Wheeler JA, Sorosky JI, Wen BC, et al.
Usefulness of tumor volumetry by magnetic resonance imaging in assessing
response to radiation therapy in carcinoma of the uterine cervix. Int J Radiat
Oncol Biol Phys. 1996;35(5):915–24.
11. Mayr NA, Wang JZ, Lo SS, Zhang D, Grecula JC, Lu L, et al. Translating response
during therapy into ultimate treatment outcome: a personalized 4-dimensional
MRI tumor volumetric regression approach in cervical cancer. Int J Radiat
Oncol Biol Phys. 2010;76(3):719–27. doi:10.1016/j.ijrobp.2009.02.036.
12. Nam H, Park W, Huh SJ, Bae DS, Kim BG, Lee JH, et al. The prognostic
significance of tumor volume regression during radiotherapy and
concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol
Oncol. 2007;107(2):320–5. doi:10.1016/j.ygyno.2007.06.022.
13. Wang JZ, Mayr NA, Zhang D, Li K, Grecula JC, Montebello JF, et al.
Sequential magnetic resonance imaging of cervical cancer: the predictive
value of absolute tumor volume and regression ratio measured before,
during, and after radiation therapy. Cancer. 2010;116(21):5093–101.
doi:10.1002/cncr.25260.
14. Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M,
Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC
ESTRO working group (II): concepts and terms in 3D image-based treatment
planning in cervix cancer brachytherapy-3D dose volume parameters and
aspects of 3D image-based anatomy, radiation physics, radiobiology.
Radiother Oncol. 2006;78(1):67–77. doi:10.1016/j.radonc.2005.11.014.
15. Harkenrider MM, Alite F, Silva SR, Small Jr W. Image-Based Brachytherapy for
the Treatment of Cervical Cancer. Int J Radiat Oncol Biol Phys. 2015;92(4):
921–34. doi:10.1016/j.ijrobp.2015.03.010.
16. Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, et al.
Clinical outcome of protocol based image (MRI) guided adaptive
brachytherapy combined with 3D conformal radiotherapy with or without
chemotherapy in patients with locally advanced cervical cancer. Radiother
Oncol. 2011;100(1):116–23. doi:10.1016/j.radonc.2011.07.012.
17. Beddy P, Rangarajan RD, Sala E. Role of MRI in intracavitary brachytherapy
for cervical cancer: what the radiologist needs to know. AJR Am J
Roentgenol. 2011;196(3):W341–7. doi:10.2214/AJR.10.5050.
18. Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, Paulino AC, et al.
Method and timing of tumor volume measurement for outcome prediction
in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol
Biol Phys. 2002;52(1):14–22.
19. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under
two or more correlated receiver operating characteristic curves: a
nonparametric approach. Biometrics. 1988;44(3):837–45.
20. Ohara K, Tanaka Y, Tsunoda H, Nishida M, Sugahara S, Itai Y. Assessment of
cervical cancer radioresponse by serum squamous cell carcinoma antigen
and magnetic resonance imaging. Obstet Gynecol. 2002;100(4):781–7.
21. Saida T, Tanaka YO, Ohara K, Oki A, Sato T, Yoshikawa H, et al. Can MRI
predict local control rate of uterine cervical cancer immediately after
radiation therapy? Magn Reson Med Sci. 2010;9(3):141–8.
22. Aubry JF, Cheung J, Morin O, Beaulieu L, Hsu IC, Pouliot J. Investigation of
geometric distortions on magnetic resonance and cone beam computed
tomography images used for planning and verification of high-dose rate
brachytherapy cervical cancer treatment. Brachytherapy. 2010;9(3):266–73.
doi:10.1016/j.brachy.2009.09.004.
23. Hellebust TP, Kirisits C, Berger D, Perez-Calatayud J, De Brabandere M, De
Leeuw A, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO
Working Group: considerations and pitfalls in commissioning and applicator
reconstruction in 3D image-based treatment planning of cervix cancer
brachytherapy. Radiother Oncol. 2010;96(2):153–60. doi:10.1016/j.radonc.
2010.06.004.
24. Zhou J, Zamdborg L, Sebastian E. Review of advanced catheter
technologies in radiation oncology brachytherapy procedures. Cancer
Manag Res. 2015;7:199–211. doi:10.2147/CMAR.S46042.
25. Dimopoulos JC, Petrow P, Tanderup K, Petric P, Berger D, Kirisits C, et al.
Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group
(IV): Basic principles and parameters for MR imaging within the frame of
image based adaptive cervix cancer brachytherapy. Radiother Oncol. 2012.
doi:10.1016/j.radonc.2011.12.024
26. Potter R, Dimopoulos J, Georg P, Lang S, Waldhausl C, Wachter-Gerstner N,
et al. Clinical impact of MRI assisted dose volume adaptation and dose
Mongula et al. Radiation Oncology  (2015) 10:252 Page 7 of 8
escalation in brachytherapy of locally advanced cervix cancer. Radiother
Oncol. 2007;83(2):148–55. doi:10.1016/j.radonc.2007.04.012.
27. (CCCMAC). CfCCM-aC. Reducing uncertainties about the effects of
chemoradiotherapy for cervical cancer: individual patient data meta-analysis.
Cochrane Database Syst Rev. 2010;20(1):CD008285. doi:10.1002/14651858.
28. Lutgens L, van der Zee J, Pijls-Johannesma M, De Haas-Kock DF, Buijsen J,
Mastrigt GA, et al. Combined use of hyperthermia and radiation therapy for
treating locally advanced cervix carcinoma. Cochrane Database Syst Rev
2010;(3):CD006377. doi:10.1002/14651858.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Mongula et al. Radiation Oncology  (2015) 10:252 Page 8 of 8
